Search results for "Multiple sclerosis"

Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.

2009

An important component of the pathogenic process of multiple sclerosis (MS) is the blood-brain barrier (BBB) damage. We recently set an in vitro model of BBB, based on a three-cell-type co-culture system, in which rat neurons and astrocytes synergistically induce brain capillary endothelial cells to form a monolayer with permeability properties resembling those of the physiological BBB. Herein we report that the serum from patients with secondary progressive multiple sclerosis (SPMS) has a damaging effect on isolated neurons. This finding suggests that neuronal damaging in MS could be a primary event and not only secondary to myelin damage, as generally assumed. SPMS serum affects the perme…

Magnetic resonance imaging in infections of the brain: findings in tuberculosis, listeriosis, toxoplasmosis, subacute sclerosing panencephalitis, and…

1987

A total of 6 patients with various inflammatory brain diseases were investigated by MRI. Typical diagnostic criteria like signal intensity, location, and morphology of the lesions are presented. MRI proves to be a highly sensitive method to detect encephalitic foci, which, however, suffers from a low specificity. Therefore additional informations like case history, clinical findings, and serological data have to be considered to find the correct diagnosis.

Direct and indirect affection of the central nervous system by Fasciola infection

2013

Fascioliasis is a worldwide, zoonotic disease caused by the liver trematodes Fasciola hepatica and Fasciola gigantica. Neurological fascioliasis has been widely reported in all continents, affecting both sexes and all ages. Two types of records related to two physiopathogenic mechanisms may be distinguished: cases in which the neurological symptoms are due to direct effects of a migrating juvenile present in the brain or neighboring organ and with cerebral lesions suggesting migration through the brain; and cases with neurological symptoms due to indirect immuno-allergic and toxic effects at distance from flukes in the liver. Neurological manifestations include minor symptoms, mainly cephal…

P23. Large demyelinating lesion of the pons as a cause of a locked-in syndrome in multiple sclerosis

2007

Multifocal Ischemic Brain-Stem Lesions

1993

The clinical symptoms and signs of brain-stem ischemia are far less well defined than in ischemia due to carotid or middle cerebral artery disease. They consist of many different syndromes, and it is often difficult to correlate the clinical findings with a single functional or morphological lesion within the brain-stem.

What is the relationship between chronic cerebrospinal venous insufficiency and multiple sclerosis?

2013

Abstract Although most of the research on multiple sclerosis was focused on its autoimmune aspects, researchers were also considering the roles of other factors, including vascular background of the disease. The idea that multiple sclerosis might be caused by stenoses of the veins draining the brain and spinal cord (the so-called chronic cerebrospinal venous insufficiency), is currently hotly debated by scientific community. Despite conflicting reports, chronic cerebrospinal venous insufficiency seems to be a real clinical phenomenon. However, it remains uncertain how it should be defined and which tests should be used for its detection. Probably this vascular abnormality should be primaril…

Four cases of progressive multifocal leukoencephalopathy in iatrogenic immunocompromised patients

2020

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) caused by John Cunningham Virus (JCV). We report four PML cases in immunocompromised patients, respectively treated with (1) Natalizumab, (2) Rituximab, (3) autologous stem-cell transplantation, and (4) Tacrolimus. All patients underwent neurological examination, magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), JCV-DNA research on biological samples, and lymphocytes subpopulation study. All cases presented with motor, behavioural, and cognitive disorders. Visual, sensitive, and cerebellar deficits developed in three cases. MRI revealed widespread progressiv…

Fingolimod (FTY720-P) Does Not Stabilize the Blood–Brain Barrier under Inflammatory Conditions in an in Vitro Model

2015

Breakdown of the blood-brain barrier (BBB) is an early hallmark of multiple sclerosis (MS), a progressive inflammatory disease of the central nervous system. Cell adhesion in the BBB is modulated by sphingosine-1-phosphate (S1P), a signaling protein, via S1P receptors (S1P\(_1\)). Fingolimod phosphate (FTY720-P) a functional S1P\(_1\) antagonist has been shown to improve the relapse rate in relapsing-remitting MS by preventing the egress of lymphocytes from lymph nodes. However, its role in modulating BBB permeabilityin particular, on the tight junction proteins occludin, claudin 5 and ZO-1has not been well elucidated to date. In the present study, FTY720-P did not change the transendotheli…

Multiple Sclerosis in Southern Europe: Monreale City, Italy

2004

<i>Background:</i> Several follow-up studies showed increasing prevalence and incidence rates for multiple sclerosis (MS). <i>Objective:</i> To ascertain, throughout a follow-up study, the incidence and prevalence of MS in the city of Monreale, Sicily, southern Italy. <i>Methods:</i> We calculated crude and age- and sex-specific prevalence rates on December 31, 2000, and determined incidence rates for the period January 1, 1992 to December 31, 2000. <i>Results:</i> The prevalence of MS was 71.2 per 100,000 population (48,5/100,000 in men; 93,0/100,000 in women). The incidence rate of MS for the period 1992–2000 was 4.0/100,000 per year. <i&…

Data of safety in a single-center alemtuzumab treated population

2020

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administr…